RHODA MADAMOMBE: Open Payments
NPI 1477131415 · ALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,359 in 51 payments from 13 companies in 2025. Trend: 2023 $783 · 2024 $1,069 · 2025 $1,359
Food & beverage: $1,359
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $357 |
| ABBVIE INC. | 14 | $326 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Alkermes, Inc. | 1 | $122 |
| Supernus Pharmaceuticals, Inc. | 5 | $112 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Noven Therapeutics, LLC | 2 | $33 |
| Lundbeck LLC | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
Products named: CAPLYTA, VRAYLAR, TRINTELLIX, LYBALVI, Qelbree, Auvelity, REXULTI, Secuado.
Industry payments across TX — which companies pay providers there.
